YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
* Addex Therapeutics press release [https://seekingalpha.com/pr/20665097-addex-therapeutics-reports-2026-half-year-results-and-provides-corporate-update] (ADXN [https://seekingalpha.com/symbol/ADXN]): 1H basic and diluted loss per share re…
Addex Therapeutics Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 28, 2026-Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small mo…
Addex Therapeutics Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 25, 2026-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company developing novel small molecule allosteric mo…
(RTTNews) - Addex Therapeutics (ADXN), a clinical-stage biopharmaceutical company, announced the publication of new preclinical research demonstrating that ADX71743, a selective negative allosteric modulator (NAM) of metabotropic glutamate…
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 30, 2026-Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modula…
(RTTNews) - Addex Therapeutics (ADXN), a clinical-stage biopharmaceutical company, on Friday announced first quarter financial results, noting a net loss due to reduced incomes. The company specializes in the development of novel small mol…
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2026-Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modula…
Geneva, Switzerland, June 22, 2026-Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today anno…
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2026-Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulat…
(RTTNews) - Addex Therapeutics Ltd. (ADXN), a clinical-stage biopharmaceutical company, announced on Wednesday that the Phase 1 trial for NTX-253 in treating schizophrenia, developed by spun-out company Neurosterix, is on track to conclude…
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 21, 2026-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric…
Data published in Molecular Psychiatry Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 3, 2026-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a por…
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 7, 2026-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteri…
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 11, 2025- Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric m…
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 4, 2025-Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric mod…
Geneva, Switzerland, December 1, 2025-Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today a…
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 29, 2025-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule alloster…
* Addex Therapeutics press release [https://seekingalpha.com/pr/20248213-addex-therapeutics-reports-2025-half-year-and-second-quarter-financial-results-and-provides] (NASDAQ:ADXN [https://seekingalpha.com/symbol/ADXN]): Q2 GAAP EPS of -CHF…
(RTTNews) - Addex Therapeutics (ADXN) Tuesday reported a net loss in its second quarter, compared to a profit last year led by sharp decrease in income. On a continuing operations basis, net loss widened from the prior year. The Swiss clin…
Cash position of CHF 2.3 million at end of H1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to phase 2 mGlu2 PAM asset, ADX71149Indivior advanced GABAB PAM substance use d…
Geneva, Switzerland, September 26, 2025- Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today an…
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 23, 2025-Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric m…
Addex Therapeutics (NASDAQ:ADXN [https://seekingalpha.com/symbol/ADXN]) has led a CHF 2 million investment [https://seekingalpha.com/pr/20151253-addex-leads-chf-2-million-investment-in-stalicla-to-advance-precision-medicine-in] in Stalicla…
Addex Therapeutics (ADXN), a small-cap biotech company with a market capitalization of $7 million, reported its Q1 2025 financial performance, revealing a decrease in income compared to the previous year but showcasing promising advancemen…
* Addex Therapeutics press release [https://seekingalpha.com/pr/20140147-addex-therapeutics-to-release-q1-2025-financial-results-and-host-conference-call-on-june-19] (NASDAQ:ADXN [https://seekingalpha.com/symbol/ADXN]): Q1 GAAP EPS of -CHF…
(RTTNews) - Addex Therapeutics Ltd. (ADXN) reported Thursday narrower net loss in its first quarter on the absence of prior year's loss from discontinued operations and lower expenses, despite sharply lower income from last year. The Swiss…
Revenue: CHF0.1 million in Q3 2024, compared to CHF0.3 million in Q3 2023. R&D Expenses: CHF0.2 million in Q3 2024, decreased by CHF0.3 million from Q3 2023. G&A Expenses: CHF0.5 million in Q3 2024, decreased by CHF5.1 million from Q3 2023…
Series A Financing: USD 63 million led by Perceptive Advisors. Equity Interest in Neurosterix: CHF 5 million and a 20% equity interest. Milestone Payments: Up to $330 million from Indivior for GABAB PAM program. Revenue: CHF 0.1 million in…
Investing.com – U.S. stocks were higher after the close on Tuesday, as gains in the Financials, Technology and Telecoms sectors led shares higher. At the close in NYSE, the Dow Jones Industrial Average rose 0.02% to hit a new all time high…
Johnson Johnson-Partner Addex Therapeutics Selects Investigational Compound For Substance Use Disorder Tuesday, Addex Therapeutics Ltd (NASDAQ:ADXN) stock is trading higher with a session volume of 3.79 million versus the average volume of…
Johnson & Johnson-Partnered Addex Therapeutics' Epilepsy Candidate Fails Mid-Stage Study, Stock Tanks Monday, Addex Therapeutics (NASDAQ:ADXN) released top-line data from a Phase 2 epilepsy study evaluating adjunctive ADX71149 (JNJ-4041181…
In this piece, we will take a look at the 15 top performing European stocks so far in 2024. If you want to skip our overview of the European economy and the stock climate, then you can skip ahead to 5 Top Performing European Stocks So Far…
In this article, we will take a look at the 15 top performing European stocks so far in 2023. To see more such companies, go directly to 5 Top Performing European Stocks So Far in 2023. The Bank of England on March 23 raised its benchmark…
Last week, Addex Therapeutics Ltd (NASDAQ: ADXN) terminated the Phase 2b/3 study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson's disease (PD-LID) due to the slow rate of patient recruitment. Adde…
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 28) Acceleron Pharma Inc. (NASDAQ: XLRN) Alker…
Gainers IronNet, Inc. (NYSE: IRNT) shares jumped 50.4% to $25.06 after jumping over 23% on Friday. Mechel PAO (NYSE: MTL) shares jumped 32.6% to $4.2443. The company recently reported Q2 results, including a 43% quarter-over-quarter revenu…